Imugene Sets March 2026 Expiry for ASX-Listed Options

Imugene ( (AU:IMU) ) has shared an update.

Imugene Limited has notified holders of its listed options on the ASX, trading under ticker IMUO, that these securities are exercisable at $0.43 each and will expire at 5:00 p.m. AEDT on 30 March 2026. Official quotation of the options will cease at the close of trading on 24 March 2026, four business days prior to expiry.

Option holders who wish to convert their holdings into Imugene shares must lodge a completed notice of exercise of options form and payment before the expiry date. The move formalises the timetable for the company’s listed options, giving investors a clear window to decide on exercising their rights and potentially increasing Imugene’s equity base ahead of the lapse of these instruments.

The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.24 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.

More about Imugene

Imugene Limited is an ASX-listed, clinical-stage immuno-oncology company focused on developing novel immunotherapies that activate the immune system to treat and eradicate tumours. Its pipeline includes the off-the-shelf allogeneic CAR T cell therapy azer-cel targeting CD19 for blood cancers, as well as oncolytic virotherapies designed for use alongside standard treatments and emerging immunotherapies for a range of cancers.

The company aims to position its platforms as foundation cancer treatments in a rapidly growing global market, supported by a team of international cancer experts and an expanding base of clinical and peer-reviewed evidence. Imugene’s strategy is to leverage its innovative technologies to improve cancer outcomes while creating value for its shareholders through leadership in next-generation immuno-oncology.

Average Trading Volume: 1,369,802

Technical Sentiment Signal: Sell

Current Market Cap: A$80.38M

For detailed information about IMU stock, go to TipRanks’ Stock Analysis page.